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OBJECTIVE—Type 1 diabetes is an autoimmune disease charac-
terized by the destruction of insulin-producing b-cells. NOD mice
provide a useful tool for understanding disease pathogenesis and
progression. Although much has been learned from studies with
NOD mice, increased understanding of human type 1 diabetes can
be gained by evaluating the pathogenic potential of human diabe-
togenic effector cells in vivo. Therefore, our objective in this study
was to develop a small-animal model using human effector cells to
study type 1 diabetes.
RESEARCH DESIGN AND METHODS—We adoptively trans-
ferred HLA-A2–matched peripheral blood mononuclear cells
(PBMCs) from type 1 diabetic patients and nondiabetic control
subjects into transgenic NOD-scid/gc
null/HLA-A*0201 (NOD-scid/
gc
null/A2) mice. At various times after adoptive transfer, we de-
termined the ability of these mice to support the survival and
proliferation of the human lymphoid cells. Human lymphocytes
were isolated and assessed from the blood, spleen, pancreatic
lymph node and islets of NOD-scid/gc
null/A2 mice after transfer.
RESULTS—Human T and B cells proliferate and survive for at
least 6 weeks and were recovered from the blood, spleen,
draining pancreatic lymph node, and most importantly, islets
of NOD-scid/gc
null/A2 mice. Lymphocytes from type 1 diabetic
patients preferentially inﬁltrate the islets of NOD-scid/gc
null/A2
mice. In contrast, PBMCs from nondiabetic HLA-A2–matched
donors showed signiﬁcantly less islet inﬁltration. Moreover, in
mice that received PBMCs from type 1 diabetic patients, we iden-
tiﬁed epitope-speciﬁcC D 8
+ T cells among the islet inﬁltrates.
CONCLUSIONS—We show that insulitis is transferred to NOD-
scid/gc
null/A2 mice that received HLA-A2–matched PBMCs from
type 1 diabetic patients. In addition, many of the inﬁltrating CD8
+
T cells are epitope-speciﬁc and produce interferon-g after in vitro
peptide stimulation. This indicates that NOD-scid/gc
null/A2 mice
transferred with HLA-A2–matched PBMCs from type 1 diabetic
patients may serve as a useful tool for studying epitope-speciﬁc
T-cell–mediated responses in patients with type 1 diabetes.
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OD mice develop spontaneous diabetes due to
autoimmune destruction of pancreatic b-cells.
These mice have served as a useful tool for
understanding many aspects of type 1 diabetes
(1,2). For example, the identiﬁcation of certain pathogenic
epitopes were originally found in NOD mice and sub-
sequently observed in the blood of type 1 diabetic patients
(3). The major shortcoming of these studies is their in-
ability to evaluate the human autoreactive effector cells
directly. Researchers have identiﬁed a number of patho-
genic autoreactive epitopes of CD4
+ and CD8
+ T cells that
recognize and result in b-cell killing. Epitopes for islet-
speciﬁc glucose-6-phosphatase catalytic subunit-related
protein (IGRP), insulin, and preproinsulin have been iden-
tiﬁed in the islets of NOD mice (4). T cells speciﬁcf o r
epitopes from these proteins and other islet proteins, in-
cluding islet amyloid polypeptide (IAPP), have been found
in the blood of type 1 diabetic patients (5). At the same time,
however, many of the ﬁndings in NOD mice have not directly
translated to human type 1 diabetes. Importantly, a large
number of therapies appear to “cure” diabetes in NOD mice,
but these therapies have not readily translated to humans.
Anti-CD3 antibody therapy, which is extremely effective in
NOD mice (6,7), is less effective in patients (8,9). These
immunomodulatory therapies still leave concerns about their
effects, as discussed by Santamaria (10). Other immune ther-
apies aimed at targeting B cells, such as anti-CD20 monoclonal
antibody treatment, also offer short-term CD19
+ B-cell de-
pletion and partially preserve b-cell function (11).
Development of humanized mice in which HLA-matched
peripheral blood mononuclear cells (PBMCs) from type 1
diabetic patients are adoptively transferred into immune-
deﬁcient mice would provide a means of studying human
immune cells without the restrictions inherent to human
studies (12). Speciﬁcally, it would be possible to identify
human autoreactive epitope-speciﬁc T cells that inﬁltrate
the islets directly ex vivo. A small-animal model that re-
capitulates the clinical manifestations of type 1 diabetes
would also assist in identifying novel therapeutic targets
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ORIGINAL ARTICLEand in developing and testing novel immunotherapeutic
agents. Furthermore, we would be able to investigate the
mechanisms involved in disease pathogenesis of many
other autoimmune diseases, especially those with disease-
associated epitopes, shared between humans and mice
(13,14).
During the past several years, many investigators have
used human hematopoietic stem cells (HSCs) for engraft-
ment into immunodeﬁcient mice (15–17). These studies
have attempted to develop a complete human immune
system in a murine host. In many cases, successful en-
graftment and cell differentiation was observed. Most re-
cently, investigators showed that functional human CD4
+
and CD8
+ T cells developed after being transferred into
immune-deﬁcient HLA transgenic mice and that these
T cells demonstrated HLA-restricted responses (18). In
contrast, our goal was not to recapitulate the entire auto-
immune process; rather, we sought to develop a hu-
manized mouse model that would be useful for identifying
pre-existing autoreactive diabetogenic circulating T cells
from type 1 diabetic patients that are important in the di-
rect pathogenesis of type 1 diabetes.
In NOD mice, b-cell–speciﬁcC D 8
+ T-cell clones are
found in the peripheral blood and pancreatic islets (19). In
patients with type 1 diabetes, epitope-speciﬁc T cells display
T-lymphocyte cytotoxic activity toward human b-cells (20).
Humans and mice also share many of the protein sequences
of identiﬁed epitopes (21). Therefore, because it is likely that
lymphocytes that have been exposed to islet antigens cir-
culate within the blood of patients with type 1 diabetes, we
adoptively transferred peripheral blood mononuclear cells
(PBMCs) from HLA-A2–matched type 1 diabetic patients into
transgenic NOD-scid/gc
null/HLA-A*0201 (NOD-scid/gc
null/A2)
mice (Table 1). NOD-scid/gc
null mice provide a lymphopenic
environment that supports the survival of human cells. We
used mice expressing a full-length human HLA gene to al-
low engagement of the human CD8 expressed on the trans-
ferred cells with exogenous HLA on the mouse cells.
Engagement of CD8 enhances both recognition and survival
of CD8 T cells (22).
After transfer of human PBMCs, we were able to show
engraftment and islet cell inﬁltration of the PBMCs from
the type 1 diabetic donors. Further, the islet-inﬁltrating
cells were enriched in T cells that recognize diabetogenic
epitopes and underwent additional expansion after trans-
fer to a secondary recipient.
RESEARCH DESIGN AND METHODS
Animals. Mice were housed in facilities approved by the Association for
Assessment and Accreditation of Laboratory Animal Care at the University
of North Carolina (UNC) Animal Facility and handled according to the UNC
Ofﬁce of Animal Care and Use. All experimentation was approved by the UNC
Institutional Animal Care and Use Committee. The original breeding pairs of
NOD.Cg-Prkdc
scid Il2rg
tm1Wjl Tg(HLA-A2.1)Enge/Sz and NOD.Cg-Prkdc
scidEmv30
b-
Tg(HLA-A/H2D/B2M)1Dvs/DvsJ mice were previously described (23,24). Ani-
mals were housed in autoclaved microisolator cages and fed autoclaved food
and chlorinated water. Mice were used at 8–14 weeks old and deﬁned as
diabetic if two consecutive weekly blood glucose measurements were
250 mg/dL.
PBMCs. All protocols involving the collection and use of PBMCs were ap-
proved by the UNC Ofﬁce of Human Research Ethics and conducted according
to Institutional Review Board Approval of Human Subjects Research.
Peripheral blood from patients diagnosed with type 1 diabetes or non-
diabetic donors (NDD) was collected under sterile conditions in heparinized
tubes. PBMCs were isolated on Ficoll-Hypaque. After isolation and puriﬁcation,
cells were tested for expression of HLA-A2 by ﬂow cytometry using ﬂuorescein
isothiocyanate–labeled BB7.2 monoclonal antibody (Abcam, Cambridge, MA).
HLA-A2
+ PBMCs from type 1 diabetic patients or NDDs were adoptively trans-
ferred into mice.
Isolation of human lymphocytes from mice. NOD-scid/gc
null/A2 mice were
intraperitoneally injected with 17–52 3 10
6 HLA-A2
+ PBMCs in 400 mL of PBS
from type 1 diabetic patients or NDD. Spleen, PLN, blood, and islets were
removed from recipient mice 2 to 6 weeks after transfer. Islets were isolated
as previously described (25). Brieﬂy, pancreata were perfused with a 2 mg/mL
solution of collagenase P (Sigma-Aldrich, St. Louis, MO), dissected, and in-
cubated at 37°C for 20 min. Islets were puriﬁed using a Ficoll PM 400 (Sigma-
Aldrich) gradient, handpicked, counted, and then cultured overnight in RPMI-
1640 containing 10% FBS and 4 ng/mL recombinant human interleukin (IL)-2
(Peprotech, Rocky Hill, NJ). Inﬁltrating lymphocytes were collected and ﬁl-
tered through a 40-µm nylon ﬁlter. Each sample constituted all of the islet cells
isolated from an individual mouse. Human cell populations were obtained by
gating on human CD45
+/mouse CD45
2. Cell suspensions were stained using
ﬂuorescently-labeled mouse antibodies to human surface markers: CD45
(PerCp), CD19 (PeCy7), CD8 (PB), CD3 (antigen-presenting cell [APC]), and
CD4 (APC-Cy7) (ebioscience, San Diego, CA), or CD3 (PO), CD3 (PTR), and
CD4 (PO) (Invitrogen, Carlsbad, CA). Samples were analyzed on a Beckman-
Coulter (Dako, Glostrup, Denmark) CyAn ADP using Summit V4.3.01 software.
Mice that had .2 3 10
6 human CD45
+ cells in their spleen were included in
our analysis.
Peptides and tetramers. Peptides IGRP265–273 (VLFGLGFAI), IA-2797–805
(MVWESGCTV), IAPP5–13 (KLQVFLIVL), and insulinB10–18 (HLVEALYLV) were
purchased from GenScript (Piscataway, NJ) at .90% purity, dissolved in
DMSO, and stored at 220°C. A2/IGRP, A2/IA-2, A2/IAPP, and A2/insulin tet-
ramers were assembled with these peptides as described (26). Brieﬂy, HLA-A2
and human b2-microglobulin were produced in Escherichia coli and refolded
with peptide in vitro. Refolded peptide major histocompatibility complex
(MHC) monomer was puriﬁed by high-performance liquid chromatography,
biotinylated using Biotin Protein Ligase, and assembled into tetramers by
conjugation with UltraAvidin-PE (Leinco, St. Louis, MO).
Interferon-g production assay. Cells (2–3 3 10
6) were incubated overnight
in complete RPMI-1640 containing 10% FBS and 4 ng/mL recombinant human
IL-2 (Peprotech). After 24 h, the cells were incubated with IGRP, IA-2, IAPP,
and insulin peptide pool or individually at 40 µg/mL of each peptide. A2/IGRP,
A2/IA-2, A2/IAPP, and A2/insulin PE-conjugated tetramers (2.5 mL each) along
with anti-CD28 (1 mg/mL) was added. Cells were incubated at 37°C, 5% CO2 for
2 h. Brefeldin A was added to inhibit protein secretion, followed by an addi-
tional 4-h incubation, placed on ice, stained with ﬂuorescently labeled surface
antibodies, ﬁxed, permeabilized, and stained with human anti-interferon (IFN)-g
monoclonal antibody (ebioscience).
TABLE 1
Type 1 diabetic and nondiabetic haplotype-matched PBMC
donors used in transfer experiments*
Patient ID Age Sex
Diabetes duration
(years)
Type 1 diabetes (n = 10)
A1 Adult F 48
A19 Adult F 41
A21 Adult M 22
A25 Adult M 12
A27 Adult M 12
A31 Adult M 25
A33 Adult M 12
A37 Adult M 22
H82 Child F 5
H96 Child F 13
NDD (n =9 )
NDD1 Adult M NA
NDD2 Adult M NA
NDD3 Adult F NA
NDD4 Adult F NA
NDD5 Adult M NA
NDD6 Adult F NA
NDD7 Adult M NA
NDD8 Adult F NA
NDD9 Adult M NA
ID, identiﬁcation; NA, not applicable. *All PBMC donors were HLA-
A2 haplotype.
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PBMCs from NDD and type 1 diabetic patients engraft
in NOD-scid/gc
null/A2 mice. Previous studies using human
HSCs have shown NOD-scid/gc
null mice support growth,
survival, and differentiation of CD34
+ HSC (17). HLA-
A2*0201 is the most commonly expressed HLA class I allele
in Europeans (45%) and is permissive for the development
of type 1 diabetes in humans and transgenic mice. There-
fore, we evaluated the ability of HLA-A2–matched PBMCs
from NDD and type 1 diabetic patients to successfully en-
graft in NOD-scid/gc
null/A2 mice. Flow cytometry analyses
conﬁrmed the presence of human CD45
+ cells in the spleen
of mice receiving PBMCs from NDD or type 1 diabetic
patients (Fig. 1A–C). Human CD45
+ cells were also found in
the blood and PLN of NOD-scid/gc
null/A2 mice (Fig. 1D and
F), albeit at lower levels. The number of human CD45
+ cells
in both groups of mice that received NDD or type 1 diabetic
PBMCs appear to be similar in the spleen (P =0 . 2 0 6 ,F i g .
1G)a n dP L N( P =0 . 3 1 7 7 ,F i g .1 H). Therefore, we de-
termined that both NDD and type 1 diabetic patient PBMCs
survive and home to the spleen (primary site of engraftment)
and PLN of NOD-scid/gc
null/A2 mice after transfer. Our data
are consistent with previously reported ﬁndings that the
primary site of engraftment by human cells in NOD-scid/
gc
null mice is the spleen (27). Interestingly, the level of en-
graftment appears to increase markedly in mice receiving
.20 3 10
6 PBMCs from patients with type 1 diabetes. Suc-
cessful engraftment was deﬁned as recovering $2 3 10
6
human CD45
+ cells from the spleen of mice that received
PBMCs. In our studies, transfer of ;30 3 10
6 PBMCs allows
for successful engraftment. This demonstrates the ability
of NOD-scid/A2/gc
null mice to support survival of PBMCs
from patients with type 1 diabetes after transfer.
PBMCs from type 1 diabetic donors proliferate in
NOD-scid/gc
null/A2 mice. To evaluate proliferation po-
tential of type 1 diabetic PBMCs in NOD-scid/g
null/A2 mice,
we labeled PBMCs with carboxyﬂuorescein succinimidyl
ester (CFSE) and conﬁrmed the presence of human CD45
+
cells in the peripheral blood, spleen, PLN, and islets of
mice after transfer. Human CD45
+ cells reconstituted in all
compartments tested. Most of the human CD45
+ cells in the
peripheral blood, spleen, PLN, and islets of NOD-scid/gc
null/
A2 mice were CFSE low, implying that many of cells un-
derwent at least ﬁve rounds of cell division (Fig. 2A–L).
FIG. 1. Human cells from type 1 diabetic (T1D) patients and NDDs engraft in NOD-scid/gc
null/A2 mice. Representative histograms of NOD-scid/
gc
null/A2 splenocytes after intraperitoneal injection of PBMCs from type 1 diabetic patients (A), NDDs (B), or scid (C). Cells were gated on human
CD45
+. At 2 to 6 weeks after transfer, summary of the percentages of human CD45
+ cells in the blood (NDDs, n = 9; type 1 diabetes, n = 10) (D),
spleen (NDD, n = 9; type 1 diabetes, n = 10) (E), and draining PLN (NDD, n = 8; type 1 diabetes, n = 10) (F) were determined by ﬂow cytometry.
The number of human CD45
+ cells in the spleen (NDD, n = 9; type 1 diabetes, n = 10) (G) and draining PLN (NDD, n = 8; type 1 diabetes, n = 10) (H)
was also evaluated. (A high-quality color representation of this ﬁgure is available in the online issue.)
HLA-A2–MATCHED PBMCS TRANSFER INSULITIS
1728 DIABETES, VOL. 60, JUNE 2011 diabetes.diabetesjournals.orgHuman T and B cells are present in the spleen and
PLN of NOD-scid/gc
null/A2 mice after transfer. Human
cells were observed in the spleen and PLN after adoptive
transfer in NOD-scid/gc
null/A2 mice. CD3
+ T cells and
CD19
+ B cells were observed in the spleen and PLN (Fig. 3).
In fact, the predominant human lymphocyte subset in the
spleen and PLN of mice was CD3
+ Tc e l l s .C D 3
+ Tc e l l si n
the spleen of mice receiving NDD or type 1 diabetic PBMCs
were 97 6 1.8% and 82 6 17.4%, respectively, of the human
CD45
+ cell population (Supplementary Fig. 1A). The level of
CD3
+ T cells in the spleen and PLN was similar in mice
receiving cells from NDDs or type 1 diabetic patients (Fig.
3A and B). The number of CD19
+ B cells in the spleen and
PLN was also similar in both groups of mice.
We compared the level of CD4
+ and CD8
+ T cells in the
spleen and PLN after transfer. Cells were gated from hCD45
+/
CD3
+ populations. The number (Fig. 3C and D) and percent-
age (Supplementary Fig. 1C and D)o fC D 4
+ and CD8
+ T cells
in the spleen and PLN was similar between both groups. In
addition, both groups of mice had similar CD4/CD8 ratios in
the spleen (Supplementary Fig. 1E) and PLN (Supplementary
Fig. 1F)a f t e rt r a n s f e r .
PBMCs from type 1 diabetic donors inﬁltrate the
islets of NOD-scid/gc
null/A2 mice at a higher frequency
than PBMCs from NDD. We determined the level of islet
inﬁltration in NOD-scid/gc
null/A2 mice receiving PBMCs
from NDD or type 1 diabetic patients. We isolated islets
from individual mice after engraftment and determined the
presence of cellular inﬁltrates. The total number of human
CD45
+ cells was signiﬁcantly higher in mice that received
type 1 diabetic PBMCs (P = 0.0006, Fig. 4A). Among these
inﬁltrates, although not widely appreciated, B cells are
found in the islets of both diabetic mice (25) and humans
(28). The level of CD3
+ Tc e l l sw a ss i g n i ﬁcantly higher in
mice that received type 1 diabetic PBMCs (P = 0.0238, Fig.
4B), whereas the level of CD19
+ B cells was similar (P =
0.1310, Fig. 4B). The percentage of CD3
+ T cells and CD19
+
B cells was similar between the two groups (Supplementary
Fig. 1G).
On a per-islet basis, the number of human CD45
+ cells
(P = 0.0006, Fig. 4C) and CD3
+ T cells (P = 0.0175, Fig. 4D)
was also increased. The level of CD19
+ B cells (P = 0.0256,
Fig. 4E) was also signiﬁcantly increased. This suggests that
although the percentages of inﬁltrating lymphocytes are
similar, the actual numbers of T and B cells are increased
in mice that received PBMCs from type 1 diabetic patients.
Human CD4 and CD8 T cells are present in the islets
of NOD-scid/gc
null/A2 mice after transfer. We de-
termined whether CD4
+ and CD8
+ T cells were present in
the islets of mice after transfer because both are required
for the development of type 1 diabetes in mice and the
issue cannot be tested in humans. The number of CD4
+
FIG. 2. Proliferation of human lymphocytes from type 1 diabetic patients in NOD-scid/gc
null/A2 mice is shown 2 weeks after transfer. PBMCs from
patients with type 1 diabetes were labeled with CFSE and transferred intraperitoneally into 8- to 14-week-old NOD-scid/g
null/A2 mice. At 2, 3, and
6 weeks after transfer of PBMCs, the proliferation of CD4
+ (top row), CD8
+ (middle row), and CD19
+ (bottom row) cells was determined by CFSE
dye dilution in cells from the blood (A, E, and I), spleen (B, F, and J), draining PLN (C, G,a n dJ), and islets (D, H,a n dL) using ﬂow cytometry.
(A high-quality color representation of this ﬁgure is available in the online issue.)
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ceived type 1 diabetic PBMCs compared with NDD PBMCs
(P = 0.0175, Fig. 4F). Although the level was not statisti-
cally signiﬁcant, CD8
+ T cells were also increased in mice
that received type 1 diabetic PBMCs (P = 0.1820, Fig. 4G).
This shows that a higher number of CD4
+ and CD8
+ T cells
from the PBMCs of type 1 diabetic patients inﬁltrate the
islets of NOD-scid/gc
null/ A 2m i c ec o m p a r e dw i t hN D D s .I n t e r -
estingly, the CD4/CD8 ratio was higher in mice that received
PBMCs from type 1 diabetic patients (Supplementary Fig. 1I).
IGRP, IAPP, insulin, and IA-2–speciﬁcC D 8
+ T cells
can be found in NOD-scid/gc
null/A2 mice transferred
with PBMCs from type 1 diabetic patients. The signif-
icant advantage of this transfer model is the potential to
identify antigen-speciﬁc CD8
+ T cells, which are important
for the development of diabetes in patients with type 1
diabetes. To understand the speciﬁcity of T cells in the
islets of NOD-scid/gc
null/A2 mice transferred with PBMCs
from type 1 diabetic patients, we used IGRP, IAPP, insulin,
and IA-2/A2 tetramers to identify epitope-speciﬁc T cells.
Lymphocytes from the spleen and islets of NOD-scid/gc
null/
A2 mice were incubated with pooled HLA-A2 tetramers
individually loaded with IGRP, IAPP, insulin, and IA-2
peptides after transfer to maximize our sensitivity of de-
tection. Figure 5A shows the number of tetramer
+ CD8
+
T cells in the islets and spleen. In fact, the level of CD8
+/
tetramer
+ T cells was signiﬁcantly higher in the islets (17–80%)
compared with the spleen (5–24%) of mice engrafted with
type 1 diabetic PBMCs. These results demonstrate that
A2-epitope–speciﬁcC D 8
+ T cells primarily inﬁltrate the
islets of mice that received type 1 diabetic PBMCs. Un-
fortunately, the sample size was not sufﬁcient to examine
the cells recovered from the islets for individual A2-tetramer
speciﬁcity.
In vitro stimulation with A2-tetramer and peptide-
induced IFN-g production by antigen-speciﬁc human
CD8
+ T cells from NOD-scid/gc
null/A2 mice after
transfer. To determine if epitope-speciﬁc human CD8
+ T
cells from the spleen and islets of mice after transfer are
functionally active, cells were incubated with pooled A2
tetramers and their respective peptides and assessed for
IFN-g production after short-term stimulation. Figure 5A
shows that CD8
+/tetramer
+ T cells are present in the
spleen (12%) and islets (15%). In addition, these epitope-
speciﬁc cells from the spleen and islets produce IFN-g
after peptide stimulation (Fig. 5B). These results demon-
strate that the islets of NOD-scid/gc
null/A2 mice contained
FIG. 3. Human T and B cells were recovered from the spleen and
draining PLN of NOD-scid/gc
null/A2 mice after transfer. Beginning at
2 weeks after transfer, ﬂow cytometry was used to determine the
number of human CD3
+ T cells and CD19
+ B cells in the spleen (A) and
PLN (B) of mice that received PBMCs from type 1 diabetic (T1D)
patients or NDDs. Cells were gated on human CD45
+ lymphocytes. The
number of CD3
+CD4
+ T cells and CD3
+CD8
+ T cells were calculated in
the spleen (C) and draining PLN (D).
FIG. 4. Human T and B cells from patients with type 1 diabetes (T1D)
inﬁltrate the islets of NOD-scid/gc
null/A2 mice after transfer. The total
number (top) of CD45
+ (A) and CD3
+ (B) T and CD19
+ B cells as well as
the number of CD45
+ (C), CD3
+ (D), CD19
+ (E), CD4
+ (F), and CD8
+
(G) cells per islet (bottom) was determined from the islets of individual
mice at 2 to 6 weeks after transfer. Islets from individual mice were
isolated as described in the RESEARCH DESIGN AND METHODS (NDDs, n =7 ;
type 1 diabetes, n = 6). *P < 0.05 and **P < 0.001, one-tailed non-
parametric Mann-Whitney test.
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+ T cells that are
capable of producing IFN-g after restimulation. Although
overt diabetes did not develop in any the mice transferred
with PBMCs from patients with type 1 diabetes, we did
observe by histology islet inﬁltration (Supplementary Fig.
2A) and elevated blood glucose levels up to 235 mg/dL
(Supplementary Fig. 2D). Mice that received NDD or type
1 diabetic PBMCs displayed no clinical signs of graft-versus-
host disease, as determined by histologic analysis of the
liver and kidney (data not shown).
IGRP, IAPP, insulin, and IA-2–speciﬁc CD8 T cells
survive after second passage into NOD-scid/gc
null/A2
mice. To determine whether epitope-speciﬁc T cells can
continue to expand from one mouse to the next, we iso-
lated splenocytes from a NOD-scid/g
null/A2 mouse that re-
ceived 20 3 10
6 type 1 diabetic PBMCs (mouse 1) and
transferred 18 3 10
6 splenocytes intraperitoneally into a
second NOD-scid/g
null/A2 mouse (mouse 2). We compared
the level of CD8
+/tetramer
+ T cells isolated from a patient
with type 1 diabetes (A21) to 1) observe the level of epitope-
speciﬁcC D 8
+ T cells after each transfer and 2) determine
if they expanded. The number and percentage of CD8
+/
tetramer
+ T cells increased from 3 3 10
3 to 7 3 10
5 cells
and in percentage from 0.06 to 6.85% (Fig. 5C and D), in the
spleen of the mouse transferred with type 1 diabetic
PBMCs. In fact, these antigen-speciﬁc CD8
+ T cells were
not only in the spleen but also in the islets of mouse 2
(Fig. 5D), demonstrating the selective expansion of epitope-
speciﬁcc e l l s .
DISCUSSION
NOD-scid/gc
null/A2 mice have been widely used to study
human immunology because these mice serve as a host for
human immune cells (13). In addition, immune-deﬁcient
mice are being used to study various human diseases, in-
cluding graft-versus-host disease after the injection of MHC-
mismatched human PBMCs (29) and also islet transplantation
rejection by mismatching MHC class I molecules of
donor PBMCs to recipient islet MHC class I molecules
(12,30).
Our goal is to study human autoimmunity, speciﬁcally
type 1 diabetes, using a humanized mouse model by
transferring HLA-A2 matched PBMCs from type 1 diabetic
patients and NDDs into NOD-scid/gc
null/A2 mice. We ob-
served proliferation and survival of T cells (CD3
+, CD4
+,
and CD8
+) and B cells for at least 6 weeks in these mice.
Similar levels of T cells in the spleen and PLN were found
in mice engrafted with PBMCs fr o mt y p e1d i a b e t i cp a t i e n t s
and NDDs; however, more B cells were found in the spleen
and PLN in mice that received PBMCs from type 1 diabetic
patients. This demonstrates the ability of human immune cell
subsets to engraft secondary lymphoid organs after transfer.
Moreover, the higher levels of B cells in the PLN and
spleen may reﬂect what occurs in the PLN and spleen of
type 1 diabetic patients. NOD-scid mice that express a
chimeric A2/K
b gene and were wild-type at the IL2r-g chain
locus were poorly engrafted (data not shown).
Through this model we have revealed an increased level
of islet inﬁltration in mice that received type 1 diabetic
PBMCs compared with NDD PBMCs. Previous studies
using NOD-scid mice and HLA-A1
+ PBMCs from type 1
diabetic patients have demonstrated the presence of islet-
reactive T cells in pancreatic tissue (31), but these T-cell
clones were not capable of intraislet inﬁltration. We have
shown here that T and B cells preferentially inﬁltrate the
islets of NOD-scid/gc
null/A2 mice that received type 1 di-
abetic PBMCs and that a signiﬁcant number of CD8
+ T
cells from the islets and spleen are speciﬁc for IGRP, IA-2,
IAP, and insulin (known diabetogenic epitopes). These
cells were found at a higher frequency in the islets com-
pared with the spleen, indicating the islets are a preferred
site of autoreactive T-cell expansion and accumulation.
Therefore, the extravasation and accumulation of human
autoreactive islet-speciﬁc T cells from circulation into the
islets suggest that PBMCs from type 1 diabetic patients are
capable of inﬁltrating the target organs necessary for the
induction of diabetes.
Circulating cytotoxic T lymphocytes isolated from HLA-
A2
+ type 1 diabetic patients have been shown to kill b-cells
through recognition of a glucose-regulated preproinsulin
epitope (18). In our model, higher frequencies of diabetogenic
epitope-speciﬁcC D 8
+ T cells from type 1 diabetic patients
inﬁltrate the islets of NOD-scid/gc
null/A2 mice. Furthermore,
these antigen speciﬁc cells are capable of producing IFN-g
after peptide stimulation.
Until now, no reported studies have demonstrated islet
inﬁltration of NOD-scid/gc
null/A2 mice by antigen-speciﬁc
T cells using HLA-A2–matched PBMCs from type 1 diabetic
patients. This may be the result of poor engraftment in
previous models that is often associated with natural killer
cell activity or the lack of human costimulatory molecules
such as human MHC molecules (32,33). We identiﬁed an
engraftment threshold and determined that 20–30 3 10
6
PBMCs is ideal for maximum engraftment in NOD-scid/
gc
null/A2 mice. This signiﬁes a size limitation for transferring
human cells into mice, which is similar to previous ﬁndings
using NOD-scid/gc
null mice (34).
Although many genetic loci contribute to the develop-
ment of diabetes, initial genome scans attribute particular
FIG. 5. A2-epitope–speciﬁc CD8
+ T cells from type 1 diabetic patients
in NOD-scid/gc
null/A2 mice. A: Percentages of CD8
+/tetramer
+ T cells
in the spleen and islets of NOD-scid/g
null/A2 mice engrafted with PBMCs
from type 1 diabetic patients (n =6 ) .B: In vitro stimulation with A2
tetramers and peptides induced the production of IFN-g from epitope-
speciﬁc CD8
+ T cells from the spleens and islets of NOD-scid/gc
null/A2
mice that received type 1 diabetic patient PBMCs (n = 5). Percentages
(C) and numbers (D) of CD8
+/tetramer
+ T cells in the spleen of mouse 1
and mouse 2 compared with the amount in the peripheral blood of a type
1 diabetic patient. D: The percentages are shown of CD8
+/tetramer
+
T cells in the islets of mouse 2.
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development of autoreactive T-cell responses in both
humans and NOD mice (35,36). The process of developing
diabetes is accelerated in NOD HLA-A2.1 MHC class I
transgenic mice and is mediated by pathogenic A2-restricted
T-cell responses (37). In humans, two islet-associated epi-
topes, IA-2 and GAD65, have been identiﬁed as being rec-
ognized by HLA-A2–restricted CD8
+ T cells, thus indicating
that CD8
+ T cells that are HLA-A2 restricted may contribute
to b-cell death. Although it is not clear whether CD8
+ Tc e l l s
are involved during the early phases of type 1 diabetes, we
do know that they are involved in the development of di-
abetes because diabetes does not develop in NOD mice
lacking MHC class I. The importance of IGRP, IAPP, IA-2,
and insulin-speciﬁcC D 8
+ T cells is still unknown in humans.
However, GAD65 and IA-2 are major islet antigens targeted
in human type 1 diabetes. The presence of an enriched
population of epitope-speciﬁcC D 8
+ T cells in the islets after
transfer may indicate the expansion of epitope-speciﬁc
immunodominant T cells from patients with type 1 diabetes
in these humanized mice.
Overt diabetes has not yet developed in any of the NOD-
scid/gc
null/A2 mice that received PBMCs from HLA-A2
+
type 1 diabetic patients, although one of the nine recipients
of type 1 diabetes HLA-A2
+ PBMCs did show elevated
blood glucose levels up to 235 mg/dL. It is likely that in
addition to the HLA-A2 molecule, this mouse model may
be improved by the addition of human MHC class II mol-
ecules or other costimulatory molecules that would allow
interaction of the donor cells with mouse cells in the
spleen and lymph node and perhaps provide a better en-
vironment for engraftment in these tissues. In the current
model, CD4
+ T cells can interact with engrafted donor
APCs via human class II only, whereas the CD8
+ T cells
can receive stimulation from both donor and recipient
(NOD-scid/gc
null/A2 mouse) cells.
It is difﬁcult to isolate large numbers of diabetogenic
CD8
+ T cells directly from the peripheral blood of patients
with type 1 diabetes. Therefore, one of the advantages of
this model is the 1,000-fold increase in epitope-speciﬁc
CD8
+ T cells observed in mice engrafted with type 1 di-
abetic PBMCs. Presumably, this will allow more studies of
human diabetogenic T cells; for example, we can test the
cross-reactivity of diabetogenic T cells to common patho-
gens. This model also allows us to identify, directly from
type 1 diabetic patients, islet epitope-speciﬁc CD8
+ T cells.
The four epitopes tested here comprised 63–88% of the
islet-inﬁltrating CD8
+ T cells in three of six mice that re-
ceived type 1 diabetic PBMCs. In the islets of the remain-
ing mice engrafted with type 1 diabetic PBMCs, these
epitopes were recognized by 19–27% of CD8
+ Tc e l li n ﬁl-
trates. In the future, we plan to use larger pools of peptides
derived from islet antigens, and this may lead to the
identiﬁcation of other islet-inﬁltrating T cells.
This model of autoimmunity may also be useful in pre-
dicting islet cell transplantation by analyzing the level of
pre-existing diabetogenic T cells in candidate patients with
type 1 diabetes. Therefore, with future developments of
this model, researchers may investigate more directly the
mechanisms underlying T cell responses. We can gain
valuable insight into the pathogenesis of various autoim-
mune diseases and predict immunotherapeutic responses.
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